Ocular Therapeutix meets SOL‑1 superiority

Wet AMD is one of those diseases where the treatment works, but the routine can wear people down. Patients often need eye injections again and again just to keep leaking blood vessels under control and preserve vision. That is why Ocular Therapeutix’s SOL-1 result matters. The company says a single dose of its axitinib implant, AXPAXLI, beat a single 2 mg aflibercept injection on the trial’s main measure at 36 weeks in treatment-naive wet AMD. ### What is AXPAXLI, exactly? AXPAXLI is an intravitreal hydrogel implant loaded with axitinib, a tyrosine kinase inhibitor that blocks VEGF signaling through a different delivery setup than standard anti-VEGF shots. The idea is simple — put a longer-acting drug depot inside the eye and stretch out control of the disease instead of chasing it with frequent reinjections. SOL-1 tested that against aflibercept, the established anti-VEGF comparator. (ophthalmologytimes.com) ### What did SOL-1 actually test? SOL-1 is a randomized, double-masked Phase 3 study in neovascular, or wet, AMD. ClinicalTrials.gov lists it as a 1:1 comparison of OTX-TKI — now branded AXPAXLI — versus aflibercept in previously untreated patients, with the primary outcome focused on maintaining vision through 36 weeks. The trial is still running for longer follow-up out to 104 weeks, but the topline readout hit the first big regulatory checkpoint. (clinicaltrials.gov) ### What was the headline result? The company’s topline says SOL-1 met its superiority primary endpoint with high statistical significance. At week 36, 74.1% of patients in the AXPAXLI arm maintained vision, versus 56.6% in the aflibercept 2 mg arm — a 17.5-point risk difference with p=0.0006. That is the part investors and retina specialists noticed immediately, because this was framed as superiority, not just noninferiority. (clinicaltrials.gov) ### Why is “single dose” the big deal? Because injection burden is the whole fight in wet AMD. A drug can look good on paper, but if patients still need to come back constantly, the practical advantage shrinks. Ocular says AXPAXLI also led on rescue-free rates — 80.6% at week 24, 74.7% at week 36, and 68.8% at week 52 — which is basically a durability signal. Fewer rescue treatments is the point of the product. (seekingalpha.com) ### Did the benefit last past week 36? At least in the company’s topline, yes. Ocular said 65.9% of AXPAXLI patients maintained vision at week 52 versus 44.2% with aflibercept, a 21.1-point difference with p<0.0001. It also reported better retinal anatomy on one prespecified exploratory measure, with 55.9% maintaining central subfield thickness within 30 microns of baseline at week 36 versus the aflibercept arm. (seekingalpha.com) ### What is the catch? Topline is not the full dataset. We still need the complete safety breakdown, subgroup performance, rescue rules in detail, and a better read on how fair the comparator setup was relative to real-world aflibercept dosing. The trial compared single doses, which makes sense for a durability claim, but clinicians will want to see the full protocol context before changing practice. (seekingalpha.com) ### What happens next? Ocular has said it plans to pursue an NDA based on SOL-1, pending discussions with the FDA, and patients in the study were re-dosed at week 52. So the near-term story is regulatory. The bigger story is competitive — if a retinal implant can show durable vision control with fewer injections, it changes what “good enough” looks like in wet AMD. (clinicaltrials.gov) ### Bottom line? This was not just a “works about as well” readout. Ocular is claiming a real superiority win in one of ophthalmology’s most crowded markets. But the market will not settle on the result until the full data show exactly how much of that edge came from stronger efficacy, cleaner durability, and acceptable safety together. (ophthalmologytimes.com) (seekingalpha.com)